Anumana

Anumana is a health technology company that specializes in AI-driven algorithms for analyzing electrocardiograms (ECGs). Founded as a joint venture between nference and Mayo Clinic, Anumana focuses on detecting and predicting early signs of cardiovascular and other medical conditions. Their technology decodes subtle electrical signals in standard ECGs, enabling earlier disease detection that traditional methods may miss. The company offers a range of FDA-cleared ECG-AI algorithms, including their lead product, ECG-AI LEF, which is designed to identify conditions like low ejection fraction and pulmonary hypertension. Anumana's software platform features a web-based dashboard that integrates these algorithms into clinical workflows and electronic health records, providing real-time decision support for clinicians. They primarily serve hospitals, health systems, and cardiology practices, aiming to enhance early disease detection and improve patient management. Anumana's commitment to clinical validation is supported by numerous peer-reviewed publications and multiple FDA Breakthrough Device Designations.

• Employees 150
• Founded 2021
• Annual Revenue $31700000